Preparation, characterization and toxicological investigation of copper loaded chitosan nanoparticles in human embryonic kidney HEK-293 cells.

Journal: Materials science & engineering. C, Materials for biological applications
Published Date:

Abstract

Metallic nanoparticles often attribute severe adverse effects to the various organs or tissues at the molecular level despite of their applications in medical, laboratory and industrial sectors. The present study highlights the preparation of copper adsorbed chitosan nanoparticles (CuCSNPs), its characterization and validation of cytotoxicity in human embryonic kidney HEK-293 cells. Particle size of the CuCSNPs was determined by using Zetasizer and the copper loading was quantified with the help of ICP/MS. Further characterization of CuCSNPs was carried out by FT-IR analysis to determine the formation of nanoparticles and SEM was conducted for the morphological analysis of the CuCSNPs. The CuCSNPs exhibited pronounced cytotoxic effects towards HEK-293 cells as analyzed by MTT assay. Moreover, the CuCSNPs inhibited the colony formation and induced nuclear damage at the dose of 100 μg/mL, much more effectively than the in built control copper sulfate (CuSO4). At the molecular level, the CuCSNPs were found to be triggering reactive oxygen species (ROS), activating effector caspases and subsequent PARP cleavage to induce cell death in HEK-293 cells.

Authors

  • Divya Arora
    Academy of Scientific and Innovative Research (AcSIR), CSIR-Indian Institute of Integrative Medicine, Jammu, India; Formulation and Drug Delivery Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
  • Vandna Dhanwal
    Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
  • Debasis Nayak
    Academy of Scientific and Innovative Research (AcSIR), CSIR-Indian Institute of Integrative Medicine, Jammu, India; Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
  • Ankit Saneja
    Academy of Scientific and Innovative Research (AcSIR), CSIR-Indian Institute of Integrative Medicine, Jammu, India; Formulation and Drug Delivery Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
  • Hina Amin
    Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
  • Reyaz Ur Rasool
    Academy of Scientific and Innovative Research (AcSIR), CSIR-Indian Institute of Integrative Medicine, Jammu, India; Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
  • Prem Narayan Gupta
    Academy of Scientific and Innovative Research (AcSIR), CSIR-Indian Institute of Integrative Medicine, Jammu, India; Formulation and Drug Delivery Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India.
  • Anindya Goswami
    Academy of Scientific and Innovative Research (AcSIR), CSIR-Indian Institute of Integrative Medicine, Jammu, India; Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Jammu, India. Electronic address: agoswami@iiim.ac.in.